| 686.36 -45.41 (-6.21%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 862.31  |
1-year : | 912.45 |
| Resists | First : | 738.28 |
Second : | 781.21 |
| Pivot price | 746.17 |
|||
| Supports | First : | 668.84 |
Second : | 556.47 |
| MAs | MA(5) : | 736.03 |
MA(20) : | 751.53 |
| MA(100) : | 759.6 |
MA(250) : | 653.87  |
|
| MACD | MACD : | -8.7 |
Signal : | -3.9 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 28.4 |
| RSI | RSI(14): 29.3 |
|||
| 52-week | High : | 820.12 | Low : | 474.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ REGN ] has closed below the lower bollinger band by 33.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ REGN ] is to continue within current trading range. Bollinger Bands are 10% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 709.86 - 714.82 | 714.82 - 718.63 |
| Low: | 656.29 - 662.8 | 662.8 - 667.79 |
| Close: | 677.21 - 686.16 | 686.16 - 693.04 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Thu, 30 Apr 2026
Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call Highl - GuruFocus
Wed, 29 Apr 2026
Regeneron Pharmaceuticals (REGN) Margins Hold Near 31% Challenging Bearish Profitability Narratives - simplywall.st
Wed, 29 Apr 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Plans $0.94 Quarterly Dividend - MarketBeat
Wed, 29 Apr 2026
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey
Wed, 29 Apr 2026
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe - Benzinga
Wed, 29 Apr 2026
Regeneron Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 90.9 (%) |
| Shares Short | 2,550 (K) |
| Shares Short P.Month | 2,290 (K) |
| EPS | 41.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 304.64 |
| Profit Margin | 31.4 % |
| Operating Margin | 23.1 % |
| Return on Assets (ttm) | 5.9 % |
| Return on Equity (ttm) | 14.8 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 61.5 |
| Sales Per Share | 138.01 |
| EBITDA (p.s.) | 40.9 |
| Qtrly Earnings Growth | -2.6 % |
| Operating Cash Flow | 4,980 (M) |
| Levered Free Cash Flow | 3,260 (M) |
| PE Ratio | 16.53 |
| PEG Ratio | 1.6 |
| Price to Book value | 2.25 |
| Price to Sales | 4.97 |
| Price to Cash Flow | 14.31 |
| Dividend | 0.93 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|